Back to All Resources

Phase 1 trial of KT-333, a STAT3 degrader, in patients with relapsed or refractory lymphomas, large granular lymphocytic leukemia and solid tumors

June 14, 2023

International Conference on Malignant Lymphoma (ICML) 2023

ICML_Poster_Thumbnail
View Poster
Area of Focus
Oncology
Programs
STAT3 (KT-333)
Indications
CTCL LGL-L PTCL Solid Tumors
Development Stage
Clinical Data
Share
LinkedInXFacebookEmailCopy Link

You may also be interested in these resources

December 12, 2022
Leveraging Pre-Clinical Animal Model of CTCL to Explore Therapeutic Potential of a Novel STAT3 Degrader
American Society of Hematology Annual Meeting and Expo
CTCL
View Resource
October 19, 2022
KT-333, A First-in-Class STAT3 Degrader, Caused Strong STAT3 Degradation and Consistent Downstream Biology In Vitro and In Vivo
20th Annual Discovery on Target Conference
Liquid Tumors Solid Tumors
View Resource
June 1, 2022
Phase 1 Study of KT-333, a Targeted Protein Degrader of STAT3, in Patients with Relapsed or Refractory Lymphomas, Large Granular Lymphocytic Leukemia, and Solid Tumors
American Society of Clinical Oncology (ASCO) 2022 Annual Meeting
CTCL LGL-L PTCL Solid Tumors
View Resource